Clinical outcomes
| Clinical outcomes, % (95% CI) . | Cryo . | Fresh . | P-value . |
|---|---|---|---|
| 2-y OS | 60 (49, 69) | 65 (58, 70) | .64 |
| 2-y PFS | 55 (46, 63) | 58 (52, 64) | .4 |
| 2-y GRFS | 41 (31, 51) | 37 (31, 43) | .45 |
| 2-y NRM | 11 (6.5, 18) | 12 (8.6, 17) | .74 |
| 2-y relapse | 34 (26, 42) | 29 (24, 35) | .28 |
| 6-mo Grade II-IV acute GVHD | 25 (18, 33) | 20 (16, 256) | .36 |
| 6-mo Grade III-IV acute GVHD | 12 (7, 18) | 8 (5, 12) | .35 |
| 2-y chronic GVHD | 39 (30, 49) | 57 (50, 63) | .00066 |
| 2-y moderate/severe chronic GVHD | 18 (10, 27) | 31 (26, 37) | .00065 |
| Tacrolimus+methotrexate and/or sirolimus GVHD prophylaxis, n (95% CI) | |||
| 2-y chronic GVHD | 42 (31, 53) | 61 (54, 68) | .0008 |
| 2-y moderate/severe chronic GVHD | 21 (12, 31) | 36 (29, 42) | .0025 |
| PTCY-based GVHD prophylaxis, n (95% CI) | |||
| 2-year chronic GVHD | 29 (14, 46) | 29 (16, 43) | .81 |
| 2-year moderate/severe chronic GVHD | 4.2 (0.3, 18) | 9.3 (3, 20) | .28 |
| Graft failure, n (%) | .18 | ||
| Yes | 7 (5.1) | 5 (2) | |
| No | 129 (94.9) | 245 (97.6) | |
| Expired before count recovery | 0 (0) | 1 (0.4) | |
| CD3 Chimerism at 1 y, % | .14 | ||
| <50% | 2 | 0 | |
| 50%-75% | 5 | 2 | |
| >75% | 93 | 98 |
| Clinical outcomes, % (95% CI) . | Cryo . | Fresh . | P-value . |
|---|---|---|---|
| 2-y OS | 60 (49, 69) | 65 (58, 70) | .64 |
| 2-y PFS | 55 (46, 63) | 58 (52, 64) | .4 |
| 2-y GRFS | 41 (31, 51) | 37 (31, 43) | .45 |
| 2-y NRM | 11 (6.5, 18) | 12 (8.6, 17) | .74 |
| 2-y relapse | 34 (26, 42) | 29 (24, 35) | .28 |
| 6-mo Grade II-IV acute GVHD | 25 (18, 33) | 20 (16, 256) | .36 |
| 6-mo Grade III-IV acute GVHD | 12 (7, 18) | 8 (5, 12) | .35 |
| 2-y chronic GVHD | 39 (30, 49) | 57 (50, 63) | .00066 |
| 2-y moderate/severe chronic GVHD | 18 (10, 27) | 31 (26, 37) | .00065 |
| Tacrolimus+methotrexate and/or sirolimus GVHD prophylaxis, n (95% CI) | |||
| 2-y chronic GVHD | 42 (31, 53) | 61 (54, 68) | .0008 |
| 2-y moderate/severe chronic GVHD | 21 (12, 31) | 36 (29, 42) | .0025 |
| PTCY-based GVHD prophylaxis, n (95% CI) | |||
| 2-year chronic GVHD | 29 (14, 46) | 29 (16, 43) | .81 |
| 2-year moderate/severe chronic GVHD | 4.2 (0.3, 18) | 9.3 (3, 20) | .28 |
| Graft failure, n (%) | .18 | ||
| Yes | 7 (5.1) | 5 (2) | |
| No | 129 (94.9) | 245 (97.6) | |
| Expired before count recovery | 0 (0) | 1 (0.4) | |
| CD3 Chimerism at 1 y, % | .14 | ||
| <50% | 2 | 0 | |
| 50%-75% | 5 | 2 | |
| >75% | 93 | 98 |